1490 O’Brien Drive
26 articles with TeneoBio, Inc.
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
Data showed results from the application of TeneoBio’s suite of technologies in the generation of the lead therapeutic candidate.
TeneoBio, Inc. And Poseida Therapeutics Announce License Agreement For The Use Of Unidab In CAR T-Cell Therapy
TeneoBio, Inc.’s Next Generation T Cell Redirection Antibody Platform For Cancer Biotherapeutics Offers Prospects Of Reducing Cytokine Release